14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $12.37 $18.22 Tuesday, 23rd Apr 2024 URGN stock ended at $14.53. This is 1.11% more than the trading day before Monday, 22nd Apr 2024. During the day the stock fluctuated 5.24% from a day low at $14.11 to a day high of $14.85.
90 days $12.37 $19.87
52 weeks $8.69 $24.13

Historical UroGen Pharma Ltd prices

Date Open High Low Close Volume
Mar 18, 2024 $14.50 $14.58 $13.83 $14.50 278 548
Mar 15, 2024 $14.49 $14.84 $13.86 $14.46 387 506
Mar 14, 2024 $16.77 $16.89 $14.14 $14.33 612 933
Mar 13, 2024 $17.83 $17.83 $16.88 $17.47 121 535
Mar 12, 2024 $17.16 $17.75 $16.84 $17.62 235 011
Mar 11, 2024 $18.10 $18.29 $16.96 $17.10 257 317
Mar 08, 2024 $18.09 $18.62 $17.70 $17.99 191 828
Mar 07, 2024 $17.80 $18.59 $17.80 $18.03 194 525
Mar 06, 2024 $18.00 $18.46 $17.88 $18.05 446 050
Mar 05, 2024 $18.37 $18.45 $17.96 $18.01 302 064
Mar 04, 2024 $17.90 $18.63 $17.47 $18.42 151 534
Mar 01, 2024 $17.32 $18.19 $16.30 $17.77 369 223
Feb 29, 2024 $18.45 $18.65 $17.90 $18.33 320 118
Feb 28, 2024 $18.32 $18.55 $17.44 $18.17 153 331
Feb 27, 2024 $18.16 $18.72 $18.00 $18.59 87 482
Feb 26, 2024 $17.05 $17.96 $17.05 $17.96 104 408
Feb 23, 2024 $17.79 $17.79 $16.94 $17.09 117 503
Feb 22, 2024 $17.68 $18.04 $17.34 $17.79 92 718
Feb 21, 2024 $19.10 $19.21 $17.54 $17.69 213 574
Feb 20, 2024 $19.18 $19.74 $19.01 $19.24 298 748
Feb 16, 2024 $18.59 $19.87 $18.15 $19.33 416 194
Feb 15, 2024 $19.22 $19.66 $18.68 $18.80 1 668 139
Feb 14, 2024 $19.01 $19.33 $18.87 $19.22 243 692
Feb 13, 2024 $18.78 $19.26 $18.44 $18.75 263 059
Feb 12, 2024 $18.98 $19.59 $18.97 $19.30 320 883
Click to get the best stock tips daily for free!

About UroGen Pharma Ltd

UroGen Pharma Ltd UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms... URGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT